A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/cd39-blockade-shows-potential-early-stage-non-small-cell-2026a1000csu?src=rss
Author :
Publish date : 2026-04-22 20:53:00
Copyright for syndicated content belongs to the linked Source.